Market Overview:
The global cabozantinib market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Cabozantinib is a type of drug that belongs to the category of tyrosine kinase inhibitors (TKIs). It is used for the treatment of medullary thyroid cancer and renal cell carcinoma. The growth in this market can be attributed to factors such as rising incidence rates of medullary thyroid cancer and renal cell carcinoma, increasing demand for targeted therapies, and growing awareness about cabozantinib. However, patent expirations for key products in this market are likely to restrain its growth over the forecast period. The global cabozantinib market can be segmented on the basis of type into capsule and tablet form. On the basis of application, it can be segmented into medullary thyroid cancer treatment and second line treatment for renal cell carcinoma. Geographically, it can be segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa .
Product Definition:
Cabozantinib is a cancer medication that is used to treat advanced renal cell carcinoma and metastatic medullary thyroid cancer. It works by blocking the activity of certain proteins that help tumors grow.
Capsule:
Capsule is a small package containing medicine substance. It's main function is to protect drug from damage & oxidation, and deliver it in targeted location. Capsules are widely used for oral drug delivery because of several advantages such as better absorption, reduced gastrointestinal irritation and interaction with other drugs, high bioavailability etc.
Tablet:
Tablet is a dosage form of cabozantinib that contains the active ingredient at a specific strength. The tablet can be administered to patients with and without oral intake issues. It is available as white or yellowish crystalline powder and has the consistency of fine sand.
Application Insights:
The market is segmented by application into medullary thyroid cancer treatment, second line treatment for renal cell carcinoma and other applications. In 2017, the medullary thyroid cancer treatment segment dominated the global cabozantinib market with a revenue share of over 80%. This can be attributed to high product penetration in this region. Medullary thyroid cancer is one of the most common types of tumor found in dogs and cats. It accounts for around 10% to 15% of all feline tumors and 5% to 10% of canine tumors across the globe.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of new technologies and increasing healthcare expenditure in this region. In addition, favorable reimbursement policies for cancer treatment are also expected to drive regional growth during the forecast period. Asia Pacific is anticipated to witness fastest growth over the forecast period owing to rising healthcare spending by governments and private organizations as well as growing awareness about advanced treatments for cancer.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the cabozantinib market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and this number is expected to rise over time. This will create a high demand for cabozantinib and other anticancer drugs.
- Rising awareness about available treatment options: There is a growing awareness among patients and healthcare professionals about available treatment options for various types of cancers including renal cell carcinoma (RCC), thyroid carcinoma, and melanoma. This is driving demand for cabozantinib as an effective treatment option for these cancers.
- Growing investment in oncology research: The pharmaceutical industry has been investing heavily in oncology research in recent years with the aim of developing novel therapies that can improve patient outcomes significantly compared to existing treatments options available currently.. Cabozantinib has emerged as one such promising therapy with significant potential to improve patient outcomes across different tumor types.. This is likely to drive its adoption over time..
Scope Of The Report
Report Attributes
Report Details
Report Title
Cabozantinib Market Research Report
By Type
Capsule, Tablet
By Application
Medullary Thyroid Cancer Treatment, Second Line Treatment for Renal Cell Carcinoma
By Companies
Exelixis, Tecoland Corporation, Fermion Oy, Sun Pharmaceutical Industries Limit, MSN Laboratories Pvt Ltd, Shanghai Hope Chem, Hetero Drugs Limited, Huateng Pharmaceutical Co., Bio Nova Pharmaceuticals Private Limited, AlchemyPharm
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
122
Number of Tables & Figures
86
Customization Available
Yes, the report can be customized as per your need.
Global Cabozantinib Market Report Segments:
The global Cabozantinib market is segmented on the basis of:
Types
Capsule, Tablet
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Medullary Thyroid Cancer Treatment, Second Line Treatment for Renal Cell Carcinoma
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Exelixis
- Tecoland Corporation
- Fermion Oy
- Sun Pharmaceutical Industries Limit
- MSN Laboratories Pvt Ltd
- Shanghai Hope Chem
- Hetero Drugs Limited
- Huateng Pharmaceutical Co.
- Bio Nova Pharmaceuticals Private Limited
- AlchemyPharm
Highlights of The Cabozantinib Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Capsule
- Tablet
- By Application:
- Medullary Thyroid Cancer Treatment
- Second Line Treatment for Renal Cell Carcinoma
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cabozantinib Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cabozantinib is a drug that is used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major companies in the cabozantinib market are Exelixis, Tecoland Corporation, Fermion Oy, Sun Pharmaceutical Industries Limit, MSN Laboratories Pvt Ltd, Shanghai Hope Chem, Hetero Drugs Limited, Huateng Pharmaceutical Co., Bio Nova Pharmaceuticals Private Limited, AlchemyPharm.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cabozantinib Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cabozantinib Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cabozantinib Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cabozantinib Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cabozantinib Market Size & Forecast, 2020-2028
4.5.1 Cabozantinib Market Size and Y-o-Y Growth
4.5.2 Cabozantinib Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Capsule
5.2.2 Tablet
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Medullary Thyroid Cancer Treatment
6.2.2 Second Line Treatment for Renal Cell Carcinoma
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cabozantinib Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cabozantinib Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Capsule
9.6.2 Tablet
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Medullary Thyroid Cancer Treatment
9.10.2 Second Line Treatment for Renal Cell Carcinoma
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Capsule
10.6.2 Tablet
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Medullary Thyroid Cancer Treatment
10.10.2 Second Line Treatment for Renal Cell Carcinoma
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Capsule
11.6.2 Tablet
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Medullary Thyroid Cancer Treatment
11.10.2 Second Line Treatment for Renal Cell Carcinoma
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Capsule
12.6.2 Tablet
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Medullary Thyroid Cancer Treatment
12.10.2 Second Line Treatment for Renal Cell Carcinoma
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Capsule
13.6.2 Tablet
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Medullary Thyroid Cancer Treatment
13.10.2 Second Line Treatment for Renal Cell Carcinoma
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cabozantinib Market: Competitive Dashboard
14.2 Global Cabozantinib Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Exelixis
14.3.2 Tecoland Corporation
14.3.3 Fermion Oy
14.3.4 Sun Pharmaceutical Industries Limit
14.3.5 MSN Laboratories Pvt Ltd
14.3.6 Shanghai Hope Chem
14.3.7 Hetero Drugs Limited
14.3.8 Huateng Pharmaceutical Co.
14.3.9 Bio Nova Pharmaceuticals Private Limited
14.3.10 AlchemyPharm
